TetraLogic to Present at the Deutsche Bank 39th Annual Healthcare Conference
April 30 2014 - 7:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that J. Kevin Buchi, President and Chief Executive
Officer, will present at the Deutsche Bank 39th Annual Healthcare
Conference on Wednesday, May 7, 2014 at 1:30 p.m. Eastern Time in
Boston, MA. Mr. Buchi will provide an overview of the Company and
its corporate activities.
The presentation will be webcast live and may be accessed by
visiting TetraLogic's website at http://ir.tetralogicpharma.com. A
replay of the webcast will be available for 10 business days.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics in
oncology and infectious diseases. TetraLogic has two clinical-stage
product candidates in development: birinapant and suberohydroxamic
acid phenyl ester (SHAPE). Birinapant is currently being tested in
Phase 1 and Phase 2 clinical trials for hematological malignancies
and solid tumors. SHAPE is entering Phase 2 trials for early-stage
CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events
or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under the heading "Risk Factors" in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March
19,2014. Any forward-looking statements contained in this
release speak only as of its date. We undertake no obligation
to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024